Tretinoin has not been studied during breastfeeding. Breastfeeding should be avoided during oral use and for 1 week after the last dose. Because it is poorly absorbed after topical application, it is considered a low risk to the nursing infant.[1] Do not apply tretinoin directly to the nipple and areola and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
A review of adverse reaction reports on retinoids causing a breast reaction submitted to a French pharmacovigilance center found 1 case of gynecomastia was associated with topical tretinoin use.[2]
Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol 2014;70:417.e1-10. [PubMed: 24528912]
2.
Atzenhoffer M, Pierre S, Bellet F, et al. Gynecomastia and galactorrhea: Unlabeled adverse drug reactions of retinoids used in dermatology. Drug Safety 2018;41:1198-9. doi:10.1007/s40264-018-0719-2 [CrossRef]
Substance Identification
Substance Name
Tretinoin
CAS Registry Number
302-79-4
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Dermatologic Agents
Keratolytic Agents
Retinoids
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
